How do you pay?

How to pay the least

Ask for the cash price

Cabometyx

We didn’t find one.

  1. Ask your pharmacy for Cabometyx’s cash price, and one or two other pharmacies too.
  2. Cabometyx’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameCabometyx
Authorized genericcabozantinib
Regular genericcabozantinib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Cabometyx?
The original
–
–

Brand nameThe maker’s card

EASE Co-Pay Program

Savings card from Exelixis

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a month

Sign up on cabometyx.com 

Or call 1-800-861-0048.

In the maker’s words

“Eligible, commercially insured patients may pay as little as $0 per month.”

From the maker’s offer on cabometyx.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Cabometyx itself, from the same company, sold without the brand name, and usually for less. For now Cabometyx is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

CABOMETYX is a kinase inhibitor indicated for the treatment of

  • patients with advanced renal cell carcinoma (RCC).
  • patients with advanced renal cell carcinoma, as a first-line treatment in combination with nivolumab
  • patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib
  • adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible
  • adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET).
  • adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors (epNET).

Source: the FDA label for Cabometyx (Exelixis, Inc.), October 19, 2025. Full label on DailyMed 

Good to know